Navigation Links
Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
Date:4/18/2013

BRIDGEWATER, New Jersey, April 18, 2013 /PRNewswire/ --

Aurigene has had a number of collaboration programs with large pharma companies over the years, and has reported successes in these programs.

     (Logo: http://photos.prnewswire.com/prnh/20130418/608115)

Elaborating on the successful collaboration programs, Aurigene's CEO CSN Murthy said "Aurigene combines its excellent execution of integrated drug discovery programs with the deep biological insights and clinical expertise of its pharma partners, and this has resulted in a very efficient model that delivers clinical candidates in timelines of 3 years or less in challenging programs."

One of Aurigene's pharma collaborations, covering 4 different programs in oncology, has seen the company delivering a clinical candidate currently in Ph 1 trials in the hands of its partner. Two other challenging programs, both potentially first-in-class molecules, are in late stages of lead optimization, with the potential to reach clinical development over the next 12-15 months. This represents a high success percentage, delivered in a highly cost-efficient and timely manner.

In another large pharma collaboration, Aurigene has been working in a niche area of inflammatory disorders, and has delivered, within 30 months of the start of the collaboration a very exciting clinical candidate for an unmet medical need. This drug candidate is in late stages of regulatory toxicology studies, and could potentially enter the clinic before the end of the current calendar year, subject to regulatory clearances. "Previous attempts to develop candidates against this target by other companies have resulted in compounds with sub-optimal properties, and could not get beyond initial clinical trials. Aurigene's candidate is the first compound against this target that has the potential to overcome the shortcomings observed in the competitor's compounds," said it
'/>"/>

SOURCE Aurigene
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Lycera Corp., a ... treat autoimmune disease and cancer, today announced that ... RORgamma agonist product candidates will be presented at ... of Cancer (SITC) being held November 6-9, 2014 ... National Harbor, MD.  The poster, entitled " Novel ...
(Date:10/31/2014)... California , November 3, 2014 ... need for men with BPH to discuss "male orgasmic ... system shows ability to treat prostate symptoms while preserving ... Inc., today welcomes the publication of a paper in ... men suffering from enlarged prostate to discuss with their ...
(Date:10/31/2014)... , October 30, 2014 ... has announced the addition of the  "Process Validation ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Science and Risk Based Approach to Process Validation ... Risk Management FDA Process Validation Guidance ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... Investment in Vaccine to Prevent Rotavirus, NEW ... that it has purchased a royalty interest in ... an oral,vaccine developed to prevent rotavirus infection, a ... infants and young children.,The product is marketed by ...
... The Public Patent,Foundation ("PUBPAT") announced today that the U.S. ... patents held by Gilead Sciences,that relate to the drug ... in the battle against HIV/AIDS. Gilead markets TDF in,the ... a part of its ATRIPLA,combination product., Roughly 40 ...
Cached Medicine Technology:Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKline's Rotarix(R) 2U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences' Claims 2
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... its kind, Rice University researchers have mapped how information ... to become metastatic. The research reveals a common pattern ... migrate and form new tumors. Researchers say the commonality ... with the genetic switches that cancer must flip to ... -- two of the main players in cancer metastasis. ...
(Date:10/31/2014)... Friday. October 31, 2014 — A team from ... and the University of California, Santa Cruz, was ... Cancer Genomics Cloud Pilot contracts with the goal ... analysis of The Cancer Genome Atlas (TCGA) and ... required computing resources in one cloud environment. This ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss ... fastest fat loss program ever developed. It promises to provide ... There is no wonder after all that this has become ... new nutrition and workout fat loss program was created by ... According to the author of this fat loss system, the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 This ... has amazing health effects for practitioners. , ... a Doctor of Science and Movement specializing in ... dedication to pelvic floor reeducation that traditional abdominal ... incontinence, Diastasis Recti, Prolepses, etc. , The Hipopressives ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3
... A research from Australian company has finalized development ... take the guesswork out of diagnosing melanomas, the ... managing director of Polartechnics said that in terms ... top specialists.// ,Image analysis and computer-aided diagnostic ...
... radiation alone may be enough to treat some patients ... France studied 60 patients between 1985 and 1999.// Typical ... patients surgery is not an option. ,In this ... eligible for surgery to remove it. A combination radiation ...
... that red wine drinkers have increased HDL cholesterol, commonly ... some light on why red wine is believed to ... HDL cholesterol levels between 40 men who drink every ... those who are heavy drinkers. As alcohol consumption shot ...
... no longer the dirty word for consumers that it was ... in eating lower fat foods. There are more than ... being fat-free or low-fat milk// products and salad dressings. ... made from starch, protein, or fat. ,Most fat substitutes ...
... the University of Michigan, made a new study ... after head and neck surgery. Ann Arbor say leeches are ... have surgery// to remove cancer in and around the head ... ,Doctors say about 15 percent of patients develop obstructions that ...
... into energy-producing muscle fibres – mocking the effect of ... protein in muscle called PGC-10.// Now, with colleagues at ... has the power to transform muscle fibres. ... is the easily-fatigued type, which is predominant among those ...
Cached Medicine News:Health News:Latest device for identifying Melanomas 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: